Danske Bank A S trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 31.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,654 shares of the biopharmaceutical company's stock after selling 34,176 shares during the period. Danske Bank A S owned about 0.07% of Regeneron Pharmaceuticals worth $55,850,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. LCM Capital Management Inc grew its position in shares of Regeneron Pharmaceuticals by 2.2% during the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company's stock worth $467,000 after buying an additional 13 shares in the last quarter. Arjuna Capital increased its stake in shares of Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after buying an additional 14 shares during the last quarter. Oakworth Capital Inc. raised its holdings in Regeneron Pharmaceuticals by 25.0% in the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 14 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in Regeneron Pharmaceuticals by 1.8% in the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company's stock valued at $645,000 after acquiring an additional 15 shares in the last quarter. Finally, Kestra Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 2.4% in the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company's stock valued at $512,000 after acquiring an additional 16 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Stock Performance
REGN stock opened at $955.47 on Monday. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $98.84 billion, a P/E ratio of 21.10, a P/E/G ratio of 1.26 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $991.73. The stock's 50 day simple moving average is $816.17 and its 200 day simple moving average is $747.36.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm's revenue for the quarter was up 36.3% on a year-over-year basis. During the same period last year, the business posted $11.83 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is 8.30%.
Insider Activity at Regeneron Pharmaceuticals
In other news, Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,652,693.38. This trade represents a 81.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Andrew Murphy sold 4,147 shares of the firm's stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock valued at $25,025,950 in the last ninety days. 6.97% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the stock. Robert W. Baird raised their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a "neutral" rating in a report on Monday, November 2nd. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a "sector perform" rating in a research note on Monday, November 2nd. Raymond James Financial increased their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Finally, TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a "buy" rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $898.97.
View Our Latest Report on REGN
Regeneron Pharmaceuticals Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.